Business Wire

Huawei Unveils the HUAWEI P20 and HUAWEI P20 Pro, Breakthroughs in Technology and Art to Redefine Intelligent Photography

Jaa

Today Huawei Consumer Business Group unveiled the HUAWEI P20 Series. The HUAWEI P20 Pro features the world’s first Leica triple camera and both devices include unprecedented AI advances, combining technology and art to bring to life a groundbreaking smartphone experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180327005811/en/

Huawei Unveils the HUAWEI P20 and HUAWEI P20 Pro, Breakthroughs in Technology and Art to Redefine In ...

Huawei Unveils the HUAWEI P20 and HUAWEI P20 Pro, Breakthroughs in Technology and Art to Redefine Intelligent Photography (Photo: Business Wire)

“We look for inspiration from artists to continuously evolve our approach to design and innovation,” said Richard Yu, Chief Executive Officer, Huawei Consumer Business Group. “With a breakthrough triple camera on the HUAWEI P20 Pro, an advanced dual camera on the HUAWEI P20 and powerful artificial intelligence on both, today’s most vibrant consumers can capture and share the brilliance of the world around them.”

Key features of the HUAWEI P20 Series include:

  • An advanced camera to capture more light, featuring a Leica triple camera and 5x Hybrid Zoom on the HUAWEI P20 Pro, and a Leica dual camera on the HUAWEI P20, both achieving DxOMark’s highest overall scores1;
  • Innovative photography features, including AI-powered professional photography features and HUAWEI AIS (AI Image Stabilization);
  • A timeless design with barely-there bezels and all-new gradient colors;
  • Ultimate performance, featuring the NPU on Kirin 970 and EMUI 8.1 based on Android™ 8.1.

A Combination of Art and Technology

The HUAWEI P20 Series comes in Black, Midnight Blue and two all-new gradient colors, Twilight and Pink Gold, achieved by applying several layers of NCVM* optical coatings underneath the glass back, so light hitting the surface refracts and creates a vivid, yet gradual change of hue.

The 5.8-inch screen HUAWEI P20 and 6.1-inch screen HUAWEI P20 Pro feature HUAWEI FullView Display, ultra-thin bezels and impressive screen-to-body ratios for better viewing experiences.

Inspired by Light and Technology

The HUAWEI P20 Pro features a Leica triple camera with the highest total pixel count on a smartphone – the camera configuration is comprised of a 40MP RGB sensor, a 20MP monochrome sensor and an 8MP sensor with telephoto lens. It also features an exclusive Leica color temperature sensor for better color reproduction. With f/1.8, f/1.6 and f/2.4 wide aperture to capture crisp, clear details, the HUAWEI P20 Pro also includes a brand new Leica 3x telephoto (VARIO-SUMMILUX-H 1:1.6-2.4/27-80ASPH) lens for long-range photography of up to 5x Hybrid Zoom. The HUAWEI P20 Pro’s highly sensitive image sensor captures low light photos with up to ISO 102400.

The HUAWEI P20 builds on its predecessor’s foundation with a Leica dual camera featuring a 12MP sensor with a pixel size as high as 1.55 μm, and a 20MP monochrome sensor, enhancing the HUAWEI P20’s ability to capture photos in low-light settings.

The HUAWEI P20 Series devices support six-axis stabilization and 960fps super slow motion. With Ultra Snapshot mode, the devices can capture an image in as little as 0.3 seconds by just double clicking the down volume button, even from an off screen.

Master AI Photography Experience

With the Kirin 970 processor, the HUAWEI P20 Series automatically identifies more than 500 scenarios in 19 categories, selecting camera settings to deliver professional-looking images. HUAWEI AIS steadies handheld night shots for incredible long exposure images without a tripod. Brand new to Huawei’s advanced camera system is 4D predictive focus, predicting moving objects and focusing on them with extreme efficiency to capture minute detail. The HUAWEI P20 Series also features AI-Assisted Composition, providing intelligent suggestions to frame group shots and landscapes.

The HUAWEI P20 and HUAWEI P20 Pro feature a 24MP selfie camera** with AI beautification and 3D portrait lighting. The HUAWEI P20 Series also includes on-device Prisma processing, which supports real-time filter recommendations based on scene and object recognition.

In partnership with Google, the HUAWEI P20 Series supports Google ARCore, delivering advanced AR capabilities.

Collaboration with Porsche Design

Huawei also unveiled the PORSCHE DESIGN HUAWEI Mate RS. Continuing its collaboration with the exclusive luxury brand, the PORSCHE DESIGN HUAWEI Mate RS features Porsche Design’s signature functional design language and Huawei’s cutting-edge technology and craftsmanship, setting a new standard in premium smartphones.

Pricing and Availability

The HUAWEI P20 Series and PORSCHE DESIGN HUAWEI Mate RS are immediately available globally.

             
Model     Version     EUR (includes tax)
HUAWEI P20     4GB + 128GB    

€649

HUAWEI P20 Pro     6GB + 128GB    

€899

PORSCHE DESIGN HUAWEI Mate RS     6GB + 256GB    

€1,695

PORSCHE DESIGN HUAWEI Mate RS     6GB + 512GB    

€2,095

       

*Non-conductive Vacuum Metalizing
**24.8MP sensor

For more information please visit: https://consumer.huawei.com/en/

1 Highest overall DxOMark scores in the mobile camera category – HUAWEI P20 Pro: 109; HUAWEI P20: 102.

Contact information

Racepoint Global for Huawei Consumer BG
Lisa Kennedy, 1-415-694-6700
Huawei@racepointglobal.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 08:00Tiedote

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 07:05Tiedote

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth16.8.2018 02:40Tiedote

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy16.8.2018 01:37Tiedote

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

QConnect – Markkinoiden älykkäin, erittäin kompakti ja lujatekoinen viestintälaite15.8.2018 23:23Tiedote

Quake Global, Inc. (QUAKE), yksi maailman johtavista IoT-markkinoiden toimittajista, julkaisi QConnect™, uuden sukupolven kehittyneen telematiikkalaitteen. Äärimmäisen kompakti QConnect integroituu kiinteisiin ja liikkuviin omaisuuksiin niiden seuraamiseksi, valvomiseksi ja hallitsemiseksi reaaliajassa mistä ja milloin tahansa. Laite tarjoaa useita pitkälle kehitettyjä langattomia kommunikaatiovaihtoehtoja, mukaan lukien LTE/2G/3G, kaksitaajuus-Wi-Fi, Bluetooth/BLE, V2X ja satelliitti. Laite on suunniteltu vastaamaan moniin eri vaatimuksiin yksinkertaisista ja edullisista seurantasovelluksista aina korkean suorituskyvyn monikanavaisiin videon suoratoistosovelluksiin. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20180815005706/fi/ Quake Global’s new QConnect, the most intelligent, global, ultra-compact and rugged communication device available (Photo: Business Wire) QConnect tarjoaa joustavuutta sen ainutlaatuisilla sovell

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 20:43Tiedote

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme